From: Is there a difference between GBS triggered by COVID-19 and those of other origins?
Variables | Post-COVID GBS n = 10 | Non-COVID GBS n = 19 | p |
---|---|---|---|
Age, mean ± SD | 55.2 ± 14.8 | 56.5 ± 15.7 | 0.836 |
Male gender, n (%) | 5 (50%) | 14 (73.7%) | 0.244 |
Comorbidities, n (%) | 7 (70%) | 10 (52.6%) | 0.449 |
Number of comorbidities, median (IQR) | 1 (0–2) | 1 (0–2) | 0.923 |
Diabetes mellitus, n (%) | 2 (20%) | 1 (5.3%) | 0.267 |
Pulmonary disease, n (%) | 0 | 1 (5.3%) | 1.000 |
Onset to hospital admission, days, median (IQR) | 6 (3–17.5) | 4 (3–7) | 0.178 |
Hospital admission before day 14, n (%) | 7 (70%) | 18 (94.7%) | 0.105 |
GDS at admission, median (IQR) | 3 (2.75–4) | 4 (2–4) | 0.701 |
GDS > 2 at admission, n (%) | 8 (80%) | 12 (63.2%) | 0.431 |
MRC-SS at admission, median (IQR) | 41.5 (38–44.5) | 46 (39–54) | 0.174 |
Cranial nerves involvement at admission, n (%) | 2 (20%) | 6 (31.6%) | 0.675 |
Facial weakness at admission, n (%) | 2 (20%) | 7 (36.8%) | 0.431 |
Bulbar weakness at admission, n (%) | 2 (20%) | 6 (31.6%) | 0.675 |
Sensitive disturbances at admission, n (%) | 10 (100%) | 13 (68.4%) | 0.068 |
Limb weakness at admission, n (%) | 10 (100%) | 18 (94.7%) | 1.000 |
Autonomic dysfunction during hospitalization, n (%) | 3 (30%) | 4 (21.1%) | 0.665 |
Onset to nadir, median (IQR), days | 10 (5–14) | 8(4–10) | 0.054 |
Nadir before day 14, n (%) | 7 (70%) | 17 (94.7%) | 0.116 |
GDS at nadir, median (IQR) | 3.5 (2.75–4.25) | 4 (2–5) | 0.670 |
GDS > 2 at nadir, n (%) | 8 (80%) | 14 (73.7%) | 1.000 |
Onset to lumbar puncture, median (IQR), days | 17 (11–27) | 13 (12–15) | 0.154 |
CSF proteins, median (IQR), mg/dL | 1.07 (0.83–3.32) | 0.64 (0.46–1.19) | 0.035 |
CSF proteins > 0.5 mg/dL, n (%) | 8/9 (88.9%) | 11/14 (78.6%) | 1.000 |
WBC in CSF, median (IQR), n/µL | 2 (0–3) | 2 (0.75–10.25) | 0.235 |
WBC in CSF > 10/µL, n (%) | 0/9 | 3/14 (21.4%) | 0.253 |
Onset to NCS, median (IQR), days | 26 (13–40) | 18 (14–22.25) | 0.090 |
NCS findings | |||
AIDP, n (%) | 7 (70%) | 14 (73.7%) | 0.486 |
AMAN, n (%) | 1 (10%) | 2 (10.5%) | |
AMSAN, n (%) | 0 | 2 (10.5%) | |
Non-defined, n (%) | 2 (20%) | 1 (5.3%) | |
Therapy | |||
IVIg, n (%) | 10 (100%) | 16 (84.2%) | |
PLEX, n (%) | 0 | 1 (5.3%) | 0.415 |
Symptomatic, n (%) | 0 | 2 (6.9%) | |
Mechanical ventilation, n (%) | 2 (20%) | 4 (21.1%) | 1.000 |
Duration of mechanical ventilation, median (IQR), days | 9.5 (8–11) | 47.5 (29.5–79.5) | 0.064 |
GDS on discharge, median (IQR) (survived) | 3.5 (1.75–4) | 3 (1–4) | 0.565 |
Adverse outcome, n (%) | 0 | 3 (15.8%) | 0.532 |
Hospital length of stay, days, median (IQR) (survived) | 16 (9–25) | 18 (12–27) | 0.33 |
Place of discharge | |||
Home, n (%) | 4 (40%) | 6 (37.5%) | |
Rehabilitation facility, n (%) | 3 (30%) | 3 (18.8%) | 0.723 |
Other hospital, n (%) | 3 (30%) | 7 (43.8%) |